Oncotalks | Powered by Novartis

Should PFS outcomes drive treatment decisions in aBC when statistical significant improvement in OS is shown?

Kisqali Channel
Share this item

Should PFS outcomes drive treatment decisions in aBC when statistical significant improvement in OS is shown?

Related items

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

Dr. Grazia Arpino is sharing her thoughts "In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor."

Kisqali Channel

00:02:23

How clinical relevance is assessed in randomized clinical trials?

How clinical relevance is assessed in randomized clinical trials?

How clinical relevance is assessed in randomized clinical trials?

Kisqali Channel

00:05:42

Is it easy to show overall survival in 1L HR+ HER2 – ABC?

Is it easy to show overall survival in 1L HR+ HER2 – ABC?

Dr. Mattea Reinisch is talking on "Is it easy to show overall survival in 1L HR+ HER2 – ABC?"

Kisqali Channel

00:03:14

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?"

Kisqali Channel

00:03:08

All CDK4/6 have shown superior OS results?

All CDK4/6 have shown superior OS results?

Dr. Michelino De Laurentiis is speaking on "ALL CDK4/6 have shown superior OS results?"

Kisqali Channel

00:03:34

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Dr. Tanja Fehm is discussing on "Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?"

Kisqali Channel

00:02:25